Aviva PLC Has $12.77 Million Holdings in Illumina, Inc. (NASDAQ:ILMN)

Aviva PLC increased its position in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 68.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 95,560 shares of the life sciences company's stock after acquiring an additional 38,678 shares during the period. Aviva PLC owned approximately 0.06% of Illumina worth $12,770,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of ILMN. Bleakley Financial Group LLC acquired a new position in shares of Illumina during the fourth quarter worth approximately $751,000. Zacks Investment Management acquired a new position in Illumina during the 3rd quarter worth $2,924,000. Van ECK Associates Corp grew its stake in shares of Illumina by 17.5% in the fourth quarter. Van ECK Associates Corp now owns 152,265 shares of the life sciences company's stock worth $20,347,000 after purchasing an additional 22,718 shares in the last quarter. Strategic Financial Concepts LLC acquired a new position in shares of Illumina during the fourth quarter valued at $1,464,000. Finally, Allworth Financial LP raised its stake in shares of Illumina by 720.7% during the fourth quarter. Allworth Financial LP now owns 7,132 shares of the life sciences company's stock valued at $1,001,000 after purchasing an additional 6,263 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors.

Illumina Stock Up 4.9 %

NASDAQ:ILMN traded up $3.52 during trading hours on Friday, hitting $74.78. 3,040,860 shares of the stock traded hands, compared to its average volume of 2,268,017. The firm has a market cap of $11.85 billion, a price-to-earnings ratio of -9.74, a PEG ratio of 1.60 and a beta of 1.38. The firm has a 50 day moving average price of $88.58 and a 200 day moving average price of $122.25. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63. Illumina, Inc. has a fifty-two week low of $68.70 and a fifty-two week high of $156.66.

Remove Ads

Illumina (NASDAQ:ILMN - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. Equities research analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the stock. TD Cowen lowered shares of Illumina from a "buy" rating to a "hold" rating and decreased their target price for the company from $177.00 to $140.00 in a research report on Friday, February 7th. HSBC cut shares of Illumina from a "buy" rating to a "hold" rating and set a $100.00 price objective for the company. in a report on Friday, February 28th. Hsbc Global Res cut Illumina from a "strong-buy" rating to a "hold" rating in a report on Friday, February 28th. Citigroup decreased their price target on Illumina from $90.00 to $85.00 and set a "neutral" rating for the company in a research note on Monday, April 7th. Finally, Barclays dropped their price objective on Illumina from $100.00 to $77.00 and set an "underweight" rating on the stock in a research note on Thursday. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $138.70.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.